Yuejin Wu1, Héctor H Valdivia2, Xander H T Wehrens2, Mark E Anderson1. 1. From the Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD (Y.W., M.E.A.); Center for Arrhythmia Research, Cardiovascular Division, Department of Internal Medicine, University of Michigan, Ann Arbor (H.H.V.); and Cardiovascular Research Institute, Departments of Molecular Physiology and Biophysics, Medicine, Pediatrics, Baylor College of Medicine, Houston, TX (X.H.T.W.). mark.anderson@jhmi.edu ywu95@jhmi.edu. 2. From the Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD (Y.W., M.E.A.); Center for Arrhythmia Research, Cardiovascular Division, Department of Internal Medicine, University of Michigan, Ann Arbor (H.H.V.); and Cardiovascular Research Institute, Departments of Molecular Physiology and Biophysics, Medicine, Pediatrics, Baylor College of Medicine, Houston, TX (X.H.T.W.).
Abstract
BACKGROUND: Fight or flight heart rate (HR) increases depend on protein kinase A (PKA)- and calmodulin kinase II (CaMKII)-mediated enhancement of Ca(2+) uptake and release from sarcoplasmic reticulum (SR) in sinoatrial nodal cells (SANC). However, the impact of specific PKA and CaMKII phosphorylation sites on HR is unknown. METHODS AND RESULTS: We systematically evaluated validated PKA and CaMKII target sites on phospholamban and the ryanodine receptor using genetically modified mice. We found that knockin alanine replacement of ryanodine receptor PKA (S2808) or CaMKII (S2814) target sites failed to affect HR responses to isoproterenol or spontaneous activity in vivo or in SANC. Similarly, selective mutation of phospholamban amino acids critical for enhancing SR Ca(2+) uptake by PKA (S16) or CaMKII (T17) to alanines did not affect HR in vivo or in SANC. In contrast, CaMKII inhibition by expression of AC3-I has been shown to slow SANC rate responses to isoproterenol and decrease SR Ca(2+) content. Phospholamban deficiency rescued SR Ca(2+) content and SANC rate responses to isoproterenol in mice with AC3-I expression, suggesting that CaMKII affects HR by modulation of SR Ca(2+) content. Consistent with this, mice expressing a superinhibitory phospholamban mutant had low SR Ca(2+) content and slow HR in vivo and in SANC. CONCLUSIONS: SR Ca(2+) depletion reduces HR and SR Ca(2+) repletion restores physiological SANC rate responses, despite CaMKII inhibition. PKA and CaMKII do not affect HR by a unique target site governing SR Ca(2+) uptake or release. HR acceleration may require an SR Ca(2+) content threshold.
BACKGROUND: Fight or flight heart rate (HR) increases depend on protein kinase A (PKA)- and calmodulin kinase II (CaMKII)-mediated enhancement of Ca(2+) uptake and release from sarcoplasmic reticulum (SR) in sinoatrial nodal cells (SANC). However, the impact of specific PKA and CaMKII phosphorylation sites on HR is unknown. METHODS AND RESULTS: We systematically evaluated validated PKA and CaMKII target sites on phospholamban and the ryanodine receptor using genetically modified mice. We found that knockin alanine replacement of ryanodine receptor PKA (S2808) or CaMKII (S2814) target sites failed to affect HR responses to isoproterenol or spontaneous activity in vivo or in SANC. Similarly, selective mutation of phospholamban amino acids critical for enhancing SR Ca(2+) uptake by PKA (S16) or CaMKII (T17) to alanines did not affect HR in vivo or in SANC. In contrast, CaMKII inhibition by expression of AC3-I has been shown to slow SANC rate responses to isoproterenol and decrease SR Ca(2+) content. Phospholamban deficiency rescued SR Ca(2+) content and SANC rate responses to isoproterenol in mice with AC3-I expression, suggesting that CaMKII affects HR by modulation of SR Ca(2+) content. Consistent with this, mice expressing a superinhibitory phospholamban mutant had low SR Ca(2+) content and slow HR in vivo and in SANC. CONCLUSIONS: SR Ca(2+) depletion reduces HR and SR Ca(2+) repletion restores physiological SANC rate responses, despite CaMKII inhibition. PKA and CaMKII do not affect HR by a unique target site governing SR Ca(2+) uptake or release. HR acceleration may require an SR Ca(2+) content threshold.
Authors: Stefan Herrmann; Peter Lipp; Kathrina Wiesen; Juliane Stieber; Huong Nguyen; Elisabeth Kaiser; Andreas Ludwig Journal: Cardiovasc Res Date: 2013-06-12 Impact factor: 10.787
Authors: Tyler P Rasmussen; Yuejin Wu; Mei-ling A Joiner; Olha M Koval; Nicholas R Wilson; Elizabeth D Luczak; Qinchuan Wang; Biyi Chen; Zhan Gao; Zhiyong Zhu; Brett A Wagner; Jamie Soto; Michael L McCormick; William Kutschke; Robert M Weiss; Liping Yu; Ryan L Boudreau; E Dale Abel; Fenghuang Zhan; Douglas R Spitz; Garry R Buettner; Long-Sheng Song; Leonid V Zingman; Mark E Anderson Journal: Proc Natl Acad Sci U S A Date: 2015-07-07 Impact factor: 11.205
Authors: Sabine Groenke; Eric D Larson; Sarah Alber; Rui Zhang; Scott T Lamp; Xiaoyan Ren; Haruko Nakano; Maria C Jordan; Hrayr S Karagueuzian; Kenneth P Roos; Atsushi Nakano; Catherine Proenza; Kenneth D Philipson; Joshua I Goldhaber Journal: PLoS One Date: 2013-11-21 Impact factor: 3.240
Authors: Yuejin Wu; Tyler P Rasmussen; Olha M Koval; Mei-Ling A Joiner; Duane D Hall; Biyi Chen; Elizabeth D Luczak; Qiongling Wang; Adam G Rokita; Xander H T Wehrens; Long-Sheng Song; Mark E Anderson Journal: Nat Commun Date: 2015-01-20 Impact factor: 14.919
Authors: Thomas M D Sheard; Miriam E Hurley; John Colyer; Ed White; Ruth Norman; Eleftheria Pervolaraki; Kaarjel K Narayanasamy; Yufeng Hou; Hannah M Kirton; Zhaokang Yang; Liam Hunter; Jung-Uk Shim; Alexander H Clowsley; Andrew J Smith; David Baddeley; Christian Soeller; Michael A Colman; Izzy Jayasinghe Journal: ACS Nano Date: 2019-02-08 Impact factor: 15.881